Dry Mouth With Conventional and Controlled-Release Oxybutynin in Urinary Incontinence

Versi, Eboo; Appell, Rodney A.; Mobley, David F.; PATTON, WALTER; Saltzstein, Daniel R.

doi:10.1097/00006250-200005000-00017

Cited by 37 publications

(62 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this evaluation, both extended-release oxybutynin chloride and tolterodine tartrate were well tolerated. Dry mouth rates were lower than those previously reported for immediate-and extended-release oxybutynin chloride [10,11,14] or tolterodine tartrate [12,17,18], and rates of central nervous system side effects (confusion, dizziness, insomnia, nervousness and somnolence) were low and similar in both treatment groups. The original OBJECT study protocol specified a twofactor ANCOVA model, with the baseline value as a covariate, and with treatment and stratum as the factors.…”

Section: Discussioncontrasting

confidence: 71%

“…Both drugs suppress involuntary bladder contractions, and oxybutynin chloride also possesses musculotropic and local anesthetic properties [9]. In earlier phase III trials, extendedrelease oxybutynin chloride reduced weekly mean urge incontinence episodes from 27.4 at baseline to 4.8 [10], and from 18.6 to 2.9 [11] in another trial. Tolterodine tartrate was shown to decrease weekly mean urge incontinence episodes from 20.3 at baseline to 9.1 in one study [12], and from 23.3 to 10.6 [13] in another.…”

Section: Introductionmentioning

confidence: 99%

“…Whereas extended-release oxybutynin chloride doses are normally titrated to levels that balance tolerability and efficacy [10,11,14], tolterodine tartrate is normally prescribed as a fixed 4-mg dose (2 mg bid) [13]. The OBJECT (Overactive Bladder: Judging Effective Control and Treatment) was the first comparative study of extended-release oxybutynin chloride and tolterodine tartrate [15].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women

Sand

Miklos

Ritter

et al. 2003

International Urogynecology Journal and Pelvic Floor Dysfunctio

Self Cite

View full text Add to dashboard Cite

Women with urge or mixed incontinence were randomized to a daily dose of 10 mg extended-release oxybutynin chloride (qd) or tolterodine tartrate 4 mg (2 mg bid) for 12 weeks. Subjects completed 7-day voiding diaries at baseline and at 12 weeks. A total of 315 women were treated. At the end of the study, extended-release oxybutynin chloride was more effective than twice-daily tolterodine tartrate as measured by urge and total incontinence episodes (p=0.038, p=0.030, respectively). Overall, the reduction in micturition frequency between groups was not significantly different. In women aged 64 years and younger (comprising 63% of the population) extended-release oxybutynin was more effective than tolterodine for urge (p=0.005) and total incontinence (p=0.005), and for micturition frequency (0.024). Adverse events were infrequent, mostly mild, and similar between treatment groups. We concluded that daily extended-release oxybutynin chloride (10 mg) was more effective than tolterodine tartrate (2 mg bid) in treating urge and total incontinence. The incidences of dry mouth, CNS events, and other adverse events were similar for both drugs.

show abstract

Section: Discussioncontrasting

confidence: 71%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women

Sand

Miklos

Ritter

et al. 2003

International Urogynecology Journal and Pelvic Floor Dysfunctio

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another controlled study comparing ecacy and safety of controlled-release oxybutynin with conventional immediate-release oxybutynin, included 226 patients with urge incontinence (Versi et al 2000). They were known to respond to anticholinergic therapy and had seven or more urge incontinence episodes per week.…”

Section: Controlled-release Oxybutyninmentioning

confidence: 99%

Oxybutynin and the overactive bladder

Andersson¹,

Chapple

2001

World J Urol

View full text Add to dashboard Cite

Oxybutynin is a tertiary amine, which undergoes an extensive first-pass metabolism. It has an active metabolite, N-desethyl oxybutynin, and the effect of oral oxybutynin is to a large extent exerted by this metabolite. Oxybutynin has both an antimuscarinic and a direct muscle relaxant effect, and, in addition, local anesthetic actions. Most probably, oral oxybutynin exerts its effects on the overactive bladder (OAB) by an antimuscarinic action. Several studies have shown that oral oxybutynin is effective in controlling OAB. Admininistred intravesically, it can increase bladder capacity and produce clinical improvement both in patients with hypereflexia and in other types of OAB with few side effects. Adverse effects related to the antimuscarinic activity occur frequently and can necessitate treatment discontinuation in up to 25% of patients, depending on the dosage. A controlled-release preparation has recently been introduced. Oxybutynin has a well-documented efficacy in the treatment of detrusor overactivity, and is a drug of first choice in patients with this disorder.

show abstract

“…[6][7][8][9] The incidence of dry mouth is high (e.g. 59.1% with oxybutynin 10) ) and is the main reason for the discontinuation of these agents.…”

mentioning

confidence: 99%

Effects of Intravenously and Orally Administered Solifenacin Succinate (YM905) on Carbachol-Induced Intravesical Pressure Elevation and Salivary Secretion in Mice

Okutsu

Noguchi

Ohtake

et al. 2007

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Dry Mouth With Conventional and Controlled-Release Oxybutynin in Urinary Incontinence

Cited by 37 publications

References 11 publications

A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women

A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women

Oxybutynin and the overactive bladder

Effects of Intravenously and Orally Administered Solifenacin Succinate (YM905) on Carbachol-Induced Intravesical Pressure Elevation and Salivary Secretion in Mice

Contact Info

Product

Resources

About